Preparation of enteric-coated capsules of beclomethasone dipropionate for patients with intestinal graft-versus-host disease and a case study

Kiminaka Murakawa, Tomoaki Sato, Yoshinobu Maeda, Yoshihisa Kitamura, Mitsune Tanimoto, Toshiaki Sendo

Research output: Contribution to journalArticle

Abstract

Graft-versus-host disease (GVHD) is a major concern in transplantation patients. Gut GVHD is accompanied by diarrhea, abdominal pain, and/or melena. Although oral treatment with corticosteroids (CSs) is effective in treating gut GVHD, it can cause adverse reactions that affect the entire body. Topical administration of CSs can be effective in treating diseases in which lesions are limited locally, because adverse reactions can then be alleviated. In this study, we examine and discuss an enteric-coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University Hospital. The BDP-EC did not dissolve in solution 1 (pHl. 2), and began disintegrating in solution 2 (pH6.8) after 5min, with a mean dissolution rate at 15min of 85%. We then used the capsule to treat a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantatioa Clinically, the frequency of diarrhea decreased after BDP-EC administration. In addition, we were able to decrease the prednisolone equivalent dose. Symptoms associated with adverse reactions to BDP were not observed during the hospitalization period. These findings suggest that the administration of BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs.

Original languageEnglish
Pages (from-to)319-324
Number of pages6
JournalActa Medica Okayama
Volume67
Issue number5
Publication statusPublished - 2013

Fingerprint

Beclomethasone
Graft vs Host Disease
Grafts
Capsules
Adrenal Cortex Hormones
Diarrhea
Transplantation (surgical)
Melena
Topical Administration
Hematopoietic Stem Cells
Prednisolone
Stem cells
Abdominal Pain
Dissolution
Hospitalization
Transplantation

Keywords

  • Beclomethasone
  • Enteric-coated capsule
  • In-hospital formulation
  • Intestinal graft-versus-host disease

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Preparation of enteric-coated capsules of beclomethasone dipropionate for patients with intestinal graft-versus-host disease and a case study. / Murakawa, Kiminaka; Sato, Tomoaki; Maeda, Yoshinobu; Kitamura, Yoshihisa; Tanimoto, Mitsune; Sendo, Toshiaki.

In: Acta Medica Okayama, Vol. 67, No. 5, 2013, p. 319-324.

Research output: Contribution to journalArticle

@article{07047b8e8e064f9eaee4ef904592059e,
title = "Preparation of enteric-coated capsules of beclomethasone dipropionate for patients with intestinal graft-versus-host disease and a case study",
abstract = "Graft-versus-host disease (GVHD) is a major concern in transplantation patients. Gut GVHD is accompanied by diarrhea, abdominal pain, and/or melena. Although oral treatment with corticosteroids (CSs) is effective in treating gut GVHD, it can cause adverse reactions that affect the entire body. Topical administration of CSs can be effective in treating diseases in which lesions are limited locally, because adverse reactions can then be alleviated. In this study, we examine and discuss an enteric-coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University Hospital. The BDP-EC did not dissolve in solution 1 (pHl. 2), and began disintegrating in solution 2 (pH6.8) after 5min, with a mean dissolution rate at 15min of 85{\%}. We then used the capsule to treat a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantatioa Clinically, the frequency of diarrhea decreased after BDP-EC administration. In addition, we were able to decrease the prednisolone equivalent dose. Symptoms associated with adverse reactions to BDP were not observed during the hospitalization period. These findings suggest that the administration of BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs.",
keywords = "Beclomethasone, Enteric-coated capsule, In-hospital formulation, Intestinal graft-versus-host disease",
author = "Kiminaka Murakawa and Tomoaki Sato and Yoshinobu Maeda and Yoshihisa Kitamura and Mitsune Tanimoto and Toshiaki Sendo",
year = "2013",
language = "English",
volume = "67",
pages = "319--324",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "5",

}

TY - JOUR

T1 - Preparation of enteric-coated capsules of beclomethasone dipropionate for patients with intestinal graft-versus-host disease and a case study

AU - Murakawa, Kiminaka

AU - Sato, Tomoaki

AU - Maeda, Yoshinobu

AU - Kitamura, Yoshihisa

AU - Tanimoto, Mitsune

AU - Sendo, Toshiaki

PY - 2013

Y1 - 2013

N2 - Graft-versus-host disease (GVHD) is a major concern in transplantation patients. Gut GVHD is accompanied by diarrhea, abdominal pain, and/or melena. Although oral treatment with corticosteroids (CSs) is effective in treating gut GVHD, it can cause adverse reactions that affect the entire body. Topical administration of CSs can be effective in treating diseases in which lesions are limited locally, because adverse reactions can then be alleviated. In this study, we examine and discuss an enteric-coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University Hospital. The BDP-EC did not dissolve in solution 1 (pHl. 2), and began disintegrating in solution 2 (pH6.8) after 5min, with a mean dissolution rate at 15min of 85%. We then used the capsule to treat a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantatioa Clinically, the frequency of diarrhea decreased after BDP-EC administration. In addition, we were able to decrease the prednisolone equivalent dose. Symptoms associated with adverse reactions to BDP were not observed during the hospitalization period. These findings suggest that the administration of BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs.

AB - Graft-versus-host disease (GVHD) is a major concern in transplantation patients. Gut GVHD is accompanied by diarrhea, abdominal pain, and/or melena. Although oral treatment with corticosteroids (CSs) is effective in treating gut GVHD, it can cause adverse reactions that affect the entire body. Topical administration of CSs can be effective in treating diseases in which lesions are limited locally, because adverse reactions can then be alleviated. In this study, we examine and discuss an enteric-coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University Hospital. The BDP-EC did not dissolve in solution 1 (pHl. 2), and began disintegrating in solution 2 (pH6.8) after 5min, with a mean dissolution rate at 15min of 85%. We then used the capsule to treat a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantatioa Clinically, the frequency of diarrhea decreased after BDP-EC administration. In addition, we were able to decrease the prednisolone equivalent dose. Symptoms associated with adverse reactions to BDP were not observed during the hospitalization period. These findings suggest that the administration of BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs.

KW - Beclomethasone

KW - Enteric-coated capsule

KW - In-hospital formulation

KW - Intestinal graft-versus-host disease

UR - http://www.scopus.com/inward/record.url?scp=84888400241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888400241&partnerID=8YFLogxK

M3 - Article

C2 - 24145732

AN - SCOPUS:84888400241

VL - 67

SP - 319

EP - 324

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 5

ER -